Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ME2 | P23368 | 1/20 | 0.65 |
| ▸ | ME1 | P48163 | 1/20 | 0.65 |
| ▸ | ME3 | Q16798 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | CNR1 | P21554 | 3/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15317642 | 0.85 | MAPT (0.62) | MAPTHDAC4HDAC6KMT2AHTT | |
| SCHEMBL4272470 | 0.83 | HRH3 (0.63) | ME2ME1ME3HRH3KMT2A | |
| SCHEMBL22587840 | 0.82 | HRH3 (0.61) | ME2ME1ME3HRH3KMT2A | |
| SCHEMBL17338907 | 0.81 | HRH3 (0.64) | MAPTHRH3HDAC4HDAC6KMT2A | |
| SCHEMBL24352145 | 0.80 | KMT2A (0.72) | ME2ME1ME3MAPTKMT2A | |
| SCHEMBL5257247 | 0.80 | MAPT (0.68) | MAPTHDAC4HDAC6KMT2AAKR1C3 | |
| SCHEMBL10174349 | 0.80 | MAPT (0.68) | MAPTKMT2AHTTSMN1; SMN2MEN1 | |
| SCHEMBL2798761 | 0.80 | L3MBTL1 (0.72) | MAPTKMT2AHTTSMN1; SMN2MEN1 | |
| SCHEMBL15650184 | 0.80 | MAPT (0.68) | MAPTHDAC4HDAC6KMT2AHTT | |
| SCHEMBL22605639 | 0.79 | HRH3 (0.62) | ME2ME1ME3HRH3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106470973-B | Small molecule L FA-1 inhibitor | 阿罗赛特制药公司 | 2020-08-04 | — | — | CN | disclosed |
| US-20190040008-A1 | SMALL MOLECULE LFA-1 INHIBITORS | ALLOCYTE PHARMACEUTICALS AG (CH) | 2019-02-07 | — | — | US | disclosed |
| US-10077238-B2 | Small molecule LFA-1 inhibitors | ALLOCYTE PHARMACEUTICALS AG (CH) | 2018-09-18 | — | — | US | disclosed |
| US-20170121284-A1 | SMALL MOLECULE LFA-1 INHIBITORS | ALLOCYTE PHARMACEUTICALS AG (CH) | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10077238-B2 | Small molecule LFA-1 inhibitors | ICAM1, VCAM1, ITGB1 | ME2 4765/4885ME1 4461/4885ME3 4848/4885 |
| US-20190040008-A1 | SMALL MOLECULE LFA-1 INHIBITORS | ICAM1, VCAM1, ITGB1 | ME2 4765/4885ME1 4461/4885ME3 4848/4885 |
| US-20170121284-A1 | SMALL MOLECULE LFA-1 INHIBITORS | ICAM1, VCAM1, ITGB1 | ME2 4765/4885ME1 4461/4885ME3 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.